These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 23905231)

  • 1. Nurses must report adverse drug reactions.
    Griffith R
    Br J Nurs; 2013 Apr 25-May 8; 22(8):484-5. PubMed ID: 23905231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reporting of adverse drug reactions by nurses.
    Morrison-Griffiths S; Walley TJ; Park BK; Breckenridge AM; Pirmohamed M
    Lancet; 2003 Apr; 361(9366):1347-8. PubMed ID: 12711472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].
    Krähenbühl S
    Ther Umsch; 2015 Dec; 72(11-12):669-71. PubMed ID: 26654809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance and communicating safety information.
    Drug Ther Bull; 2012 Dec; 50(12):138-40. PubMed ID: 23241564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals.
    Rehan HS; Chopra D; Holani SN; Mishra R
    Int J Risk Saf Med; 2014; 26(1):1-8. PubMed ID: 24796346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting.
    Lorimer S; Cox A; Langford NJ
    J Clin Pharm Ther; 2012 Apr; 37(2):148-52. PubMed ID: 21592157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nurse reporting of adverse events caused by medicines.
    Hunt JM; Gjoka G
    Nurs Times; 2003 Dec 9-15; 99(49):24-5. PubMed ID: 14705341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme.
    O' Donovan B; Rodgers RM; Cox AR; Krska J
    Br J Clin Pharmacol; 2022 Jul; 88(7):3434-3446. PubMed ID: 35128732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
    Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media.
    Ghosh R; Lewis D
    Expert Opin Drug Saf; 2015; 14(12):1845-53. PubMed ID: 26436834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
    Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions: classification, susceptibility and reporting.
    Kaufman G
    Nurs Stand; 2016 Aug; 30(50):53-63. PubMed ID: 27507394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nurses' spontaneous reporting of adverse drug reactions: expert review of routine reports.
    Mendes D; Alves C; Batel Marques F
    J Nurs Manag; 2014 Apr; 22(3):322-30. PubMed ID: 24754750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Editorial: adverse drug reactions].
    Taegtmeyer AB
    Ther Umsch; 2015 Dec; 72(11-12):667. PubMed ID: 26654808
    [No Abstract]   [Full Text] [Related]  

  • 18. Veterinary pharmacovigilance. Part 2. Veterinary pharmacovigilance in practice -- the operation of a spontaneous reporting scheme in a European Union country -- the UK, and schemes in other countries.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):149-70. PubMed ID: 15842305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
    Santoro A; Genov G; Spooner A; Raine J; Arlett P
    Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.